Brief: FSD Pharma Arbitration Panel Finds That Syneos Health "Failed To Use Commercially Reasonable Efforts" In Conducting Its Trial For FSD 201
17/07/2023 23:11
July 17 (Reuters) - FSD Pharma Inc HUGE.CD :
* FSD PHARMA INC: ARBITRATION PANEL FINDS THAT SYNEOS HEALTH
"FAILED TO USE COMMERCIALLY REASONABLE EFFORTS" IN CONDUCTING
ITS TRIAL FOR FSD 201
Source text for Eikon: ID:nBw211Cvya
Further company coverage: HUGE.CD
(Reuters.Briefs@thomsonreuters.com)
Recent news on Syneos Health
See all newsHayward Holdings rises on S&P Smallcap 600 inclusion
Brief: Syneos Health And Oracle To Expand Partnership
Large LBO bond sales could prompt September US junk debt rush
Brief: SYNEOS HEALTH AND STAR PARENT ANNOUNCE PROPOSED $1.70 BILLION OFFERING OF SENIOR SECURED NOTES
Brief: Syneos Health Announces Agreement With Aotearoa Clinical Trials, Expanding Clinical Trial Capabilities Across Range Of Therapeutic Areas In New Zealand